Moderna said a new mRNA vaccine candidate delivered strong protection against the latest SARS-CoV-2 subvariant in a global Phase 3 trial, with results showing 87% efficacy. The findings were published in The New England Journal of Medicine and are being presented as a potential step forward as the virus continues to evolve.

According to the company, the trial enrolled participants across multiple countries and assessed the vaccine’s ability to prevent symptomatic infection from the emerging strain. While the reported efficacy is notable, researchers will still need to monitor how durable the protection is and whether the vaccine performs similarly in broader real-world use.

The result comes as health officials and pharmaceutical developers continue to adapt to shifting COVID-19 variants that have repeatedly challenged existing immunization strategies. Any eventual rollout would depend on further regulatory review, manufacturing plans, and updated public-health guidance.

The latest data adds to the body of evidence supporting mRNA technology as a flexible platform for responding to new viral threats, even as scientists stress that ongoing surveillance remains essential.